Urologic cancers, including prostate, bladder, kidney, urothelial upper tract, testicular, penile, and urethral cancer, are on the rise. The Smilow Cancer Hospital Prostate and Urologic Cancers Program at Yale Medicine is uniquely qualified to treat these cancers.
Our program utilizes the most advanced technology and techniques available to diagnose, manage, and treat urologic cancers. We are leaders in the use of MRI/US Fusion prostate biopsy (which blends MRI and ultrasound for increased accuracy), utilizing the Artemis system. This technology allows us to detect the cancer early and closely monitor it. When surgery is needed, our urologists provide extensive expertise in nerve-sparing laparoscopic and robotic surgery, traditional open surgery, and novel targeted or "focal" treatments.
Our medical oncologists have pioneered numerous treatments for patients with advanced cancers, including the discovery of the first truly effective treatment for metastatic prostate cancer and advanced immunotherapy treatments for prostate, bladder, and kidney cancers.
Patients who need radiation therapy can feel confident that they are receiving the highest quality care from an experienced team of radiation oncologists who utilize cutting-edge, 3D radiation therapy technology. Other advancements, such as the SpaceOAR system, which is a gel spacer placed by a urologist between the prostate and rectum before radiation therapy, enables our multidisciplinary care team to treat advanced prostate cancer, while minimizing side effects for our patients.
Smilow Cancer Hospital and Yale Cancer Center are at the forefront of cancer research, offering a variety of clinical trials. It is our goal to diagnose, manage, and treat urologic conditions in minimally invasive ways so that patients experience fewer side effects, spend less time in the hospital, and recover faster.